SAVIMS

SAVIMS logo white
Menu

August 2021

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

German Doctors and Lawyers Raise Concerns Over Covid Injections

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Wilson, R. (2021, August 31). German doctors and lawyers assess blood smears from people who have had Covid injections: “For me this is euthanasia. For me this is mass murder, a crime on a grand scale.” Expose News. https://expose-news.com/2021/08/31/german-doctors-and-lawyers-assess-blood-smears-from-people-who-have-had-covid-injections-for-me-this-is-euthanasia-for-me-this-is-mass-murder-a-crime-on-a-grand-scale Summary: The article discusses alarming findings from German doctors and lawyers regarding the blood of […]

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Overview of the Main Anti-SARS-CoV-2 Vaccines

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021). Overview of the main anti-SARS-CoV-2 vaccines: Mechanism of action, efficacy and safety. Infection and Drug Resistance, 14, 3459–3476. https://doi.org/10.2147/IDR.S315727 Summary: The article reviews the principal vaccines developed against SARS-CoV-2 during the Covid-19 pandemic, detailing their mechanisms of action, efficacy, safety, and

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

SARS-CoV-2 mRNA Vaccination and Myocarditis in Adolescents

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Høeg, T. B., Krug, A., Stevenson, J., & Mandrola, J. (2021). SARS-CoV-2 mRNA vaccination-associated myocarditis in children ages 12-17: A stratified national database analysis. medRxiv. https://doi.org/10.1101/2021.08.30.21262866 Summary: This study investigates the incidence of myocarditis in adolescents aged 12-17 following mRNA COVID-19 vaccinations. Using data from the Vaccine Adverse Event Reporting System (VAERS), the authors

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

The Risks of mRNA Vaccination in Adolescents: Myocarditis Concerns

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Høeg, T. B., Krug, A., Stevenson, J., & Mandrola, J. (2021). SARS-CoV-2 mRNA vaccination-associated myocarditis in children ages 12-17: A stratified national database analysis. medRxiv. https://doi.org/10.1101/2021.08.30.21262866 Summary: This article investigates the incidence of myocarditis following mRNA COVID-19 vaccination in children aged 12-17, as reported through the Vaccine Adverse Event Reporting System (VAERS). It highlights

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

US COVID-19 Vaccines: A Critical Analysis of Health Impact

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Classen, B. (2021). US COVID-19 vaccines proven to cause more harm than good based on pivotal clinical trial data analysed using the proper scientific endpoint, “all cause severe morbidity”. Trends in Internal Medicine, 1(1), 1-6. Summary: The article by J. Bart Classen critiques the three COVID-19 vaccines approved in the US, asserting that they

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Comparing SARS-CoV-2 Natural Immunity to Vaccine-Induced Immunity

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Cohen, D., Muhsen, K., Chodick, G., & Patalon, T. (2021). Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. medRxiv. https://doi.org/10.1101/2021.08.24.21262415 Summary: This study compares the long-term protection provided by natural immunity from previous SARS-CoV-2 infection to that from the

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Kinetics of Antibody Decay After BNT162b2 Vaccination vs. SARS-CoV-2 Infection

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan-Cohen, A., Schäffer, A. A., Ruppin, E., Magen, E., & Vinker, S. (2021). Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. medRxiv. https://doi.org/10.1101/2021.08.03.21261496 Summary: This study investigates the decay of SARS-CoV-2 IgG antibodies in individuals vaccinated with two doses of

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

SAHPRAs Monitoring of COVID-19 Vaccine Adverse Events

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: South African Health Products Regulatory Authority. (2021, August 20). SAHPRA statement on adverse events following immunisation (AEFIs) with COVID-19 vaccines. Summary: The South African Health Products Regulatory Authority (SAHPRA) oversees the safety of COVID-19 vaccines in collaboration with the National Department of Health (NDoH). Since the national vaccination roll-out commenced on 17 May 2021,

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. Morbidity and Mortality Weekly Report, 70(32), 1081-1083. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7032e1-H.pdf Summary: A study conducted in Kentucky during May-June 2021 assessed the impact of COVID-19 vaccination on reinfection rates among individuals previously

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reduced Reinfection Risk with Vaccination in Previously Infected Individuals

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021). Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination – Kentucky, May–June 2021. Morbidity and Mortality Weekly Report, 70(32), 1081-1083. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7032e1-H.pdf Summary: A study conducted in Kentucky investigated the impact of COVID-19 vaccination on reinfection rates among individuals previously infected

Scroll to Top